Do analysts recommend BFRI or ZYBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, BFRI or ZYBT?

Zhengye Biotechnology has lower revenue, but higher earnings than Biofrontera. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biofrontera $46.18M 0.51 -$10.54M -$0.45 N/A Zhengye Biotechnology $16.64M 4.93 -$9.98M N/A N/A

Do analysts prefer BFRI or ICCC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BFRI or ICCC more profitable?

ImmuCell has a net margin of 2.57% compared to Biofrontera's net margin of -13.78%. ImmuCell's return on equity of 2.69% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets Biofrontera -13.78% -145.81% -31.30% ImmuCell 2.57% 2.69% 1.76%

Do analysts rate BFRI or TENX?

Tenax Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 557.28%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenax Therapeutics is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tenax Therapeutics 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.56

Do analysts prefer CING or BFRI?

Cingulate currently has a consensus target price of $27.00, suggesting a potential upside of 407.52%. Given Cingulate's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cingulate is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CING or BFRI more profitable?

Cingulate has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -238.40% -128.67% Biofrontera -13.78% -145.81% -31.30%

Do analysts rate BFRI or VRCA?

Verrica Pharmaceuticals has a consensus target price of $12.67, suggesting a potential upside of 122.61%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Verrica Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Biofrontera (BFRI) Competitors

$1.59 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$1.61 +0.02 (+1.19%)

As of 04:22 AM Eastern

Compare

BFRI vs. ZYBT, ICCC, TENX, CING, and VRCA

Should you buy Biofrontera stock or one of its competitors? Biofrontera's main competitors and comparable companies include Zhengye Biotechnology (ZYBT), ImmuCell (ICCC), Tenax Therapeutics (TENX), Cingulate (CING), and Verrica Pharmaceuticals (VRCA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Biofrontera compare to Zhengye Biotechnology?

Biofrontera (NASDAQ:BFRI) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Biofrontera has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.74, indicating that its share price is 374% less volatile than the broader market.

In the previous week, Biofrontera and Biofrontera both had 2 articles in the media. Biofrontera's average media sentiment score of 1.44 beat Zhengye Biotechnology's score of 0.94 indicating that Biofrontera is being referred to more favorably in the media.

Company	Overall Sentiment
Biofrontera	Positive
Zhengye Biotechnology	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.1% of Biofrontera shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zhengye Biotechnology has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Zhengye Biotechnology's return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Zhengye Biotechnology	N/A	N/A	N/A

Zhengye Biotechnology has lower revenue, but higher earnings than Biofrontera.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$46.18M	0.51	-$10.54M	-$0.45	N/A
Zhengye Biotechnology	$16.64M	4.93	-$9.98M	N/A	N/A

Summary

Biofrontera beats Zhengye Biotechnology on 7 of the 12 factors compared between the two stocks.

How does Biofrontera compare to ImmuCell?

Biofrontera (NASDAQ:BFRI) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Biofrontera has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

ImmuCell has a net margin of 2.57% compared to Biofrontera's net margin of -13.78%. ImmuCell's return on equity of 2.69% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
ImmuCell	2.57%	2.69%	1.76%

ImmuCell has lower revenue, but higher earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$46.18M	0.51	-$10.54M	-$0.45	N/A
ImmuCell	$27.64M	3.27	-$1.04M	$0.08	124.25

10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by insiders. Comparatively, 5.7% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Biofrontera had 1 more articles in the media than ImmuCell. MarketBeat recorded 2 mentions for Biofrontera and 1 mentions for ImmuCell. Biofrontera's average media sentiment score of 1.44 equaled ImmuCell'saverage media sentiment score.

Company	Overall Sentiment
Biofrontera	Positive
ImmuCell	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

ImmuCell beats Biofrontera on 8 of the 13 factors compared between the two stocks.

How does Biofrontera compare to Tenax Therapeutics?

Biofrontera (NASDAQ:BFRI) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Tenax Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Tenax Therapeutics' return on equity of -61.54% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Tenax Therapeutics	N/A	-61.54%	-57.42%

10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by company insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Biofrontera has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Biofrontera has higher revenue and earnings than Tenax Therapeutics. Biofrontera is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$46.18M	0.51	-$10.54M	-$0.45	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Tenax Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 557.28%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenax Therapeutics is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tenax Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, Tenax Therapeutics had 13 more articles in the media than Biofrontera. MarketBeat recorded 15 mentions for Tenax Therapeutics and 2 mentions for Biofrontera. Tenax Therapeutics' average media sentiment score of 1.50 beat Biofrontera's score of 1.44 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biofrontera	Positive
Tenax Therapeutics	Positive

Summary

Tenax Therapeutics beats Biofrontera on 11 of the 16 factors compared between the two stocks.

How does Biofrontera compare to Cingulate?

Cingulate (NASDAQ:CING) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Cingulate has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-238.40%	-128.67%
Biofrontera	-13.78%	-145.81%	-31.30%

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 10.1% of Biofrontera shares are owned by institutional investors. 5.3% of Cingulate shares are owned by insiders. Comparatively, 8.1% of Biofrontera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Biofrontera has higher revenue and earnings than Cingulate. Biofrontera is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$3.59	N/A
Biofrontera	$46.18M	0.51	-$10.54M	-$0.45	N/A

Cingulate currently has a consensus target price of $27.00, suggesting a potential upside of 407.52%. Given Cingulate's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cingulate is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cingulate had 9 more articles in the media than Biofrontera. MarketBeat recorded 11 mentions for Cingulate and 2 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.44 beat Cingulate's score of -0.24 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Overall Sentiment
Cingulate	Neutral
Biofrontera	Positive

Cingulate has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Summary

Biofrontera beats Cingulate on 8 of the 15 factors compared between the two stocks.

How does Biofrontera compare to Verrica Pharmaceuticals?

Biofrontera (NASDAQ:BFRI) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Biofrontera has higher revenue and earnings than Verrica Pharmaceuticals. Biofrontera is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$46.18M	0.51	-$10.54M	-$0.45	N/A
Verrica Pharmaceuticals	$35.58M	2.75	-$17.89M	-$1.67	N/A

Biofrontera has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Biofrontera has a net margin of -13.78% compared to Verrica Pharmaceuticals' net margin of -102.84%. Biofrontera's return on equity of -145.81% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%

In the previous week, Verrica Pharmaceuticals had 5 more articles in the media than Biofrontera. MarketBeat recorded 7 mentions for Verrica Pharmaceuticals and 2 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.44 beat Verrica Pharmaceuticals' score of 0.41 indicating that Biofrontera is being referred to more favorably in the media.

Company	Overall Sentiment
Biofrontera	Positive
Verrica Pharmaceuticals	Neutral

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 8.1% of Biofrontera shares are held by insiders. Comparatively, 52.9% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Verrica Pharmaceuticals has a consensus target price of $12.67, suggesting a potential upside of 122.61%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Verrica Pharmaceuticals beats Biofrontera on 9 of the 16 factors compared between the two stocks.

Get Biofrontera News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BFRI vs. The Competition

Export

Metric	Biofrontera	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$23.62M	$12.11B	$7.18B	$12.89B
Dividend Yield	N/A	2.62%	2.54%	11.27%
P/E Ratio	-3.53	787.65	273.17	25.45
Price / Sales	0.51	759.94	638.21	103.75
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	1.77	10.49	11.08	6.36
Net Income	-$10.54M	$2.83B	$3.48B	$349.79M
7 Day Performance	8.90%	0.58%	0.38%	-0.40%
1 Month Performance	35.90%	5.69%	7.89%	4.24%
1 Year Performance	79.44%	6.19%	24.71%	15.13%

Biofrontera Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BFRI Biofrontera	1.4676 of 5 stars	$1.59 flat	N/A	+79.4%	$23.62M	$46.18M	N/A	70	Positive News Short Interest Decrease Gap Down
ZYBT Zhengye Biotechnology	0.3209 of 5 stars	$1.83 -3.2%	N/A	-81.5%	$89.57M	$16.64M	N/A	278	Gap Up
ICCC ImmuCell	1.9316 of 5 stars	$10.02 +1.8%	N/A	+55.3%	$89.37M	$27.64M	125.27	70
TENX Tenax Therapeutics	4.1588 of 5 stars	$2.12 -8.6%	$14.00 +560.4%	-64.4%	$86.82M	N/A	N/A	9	Positive News Short Interest Increase
CING Cingulate	2.5548 of 5 stars	$5.40 -8.0%	$27.00 +400.0%	+33.3%	$85.36M	N/A	N/A	20	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BFRI) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biofrontera (BFRI) Competitors

BFRI vs. ZYBT, ICCC, TENX, CING, and VRCA

How does Biofrontera compare to Zhengye Biotechnology?

Summary

How does Biofrontera compare to ImmuCell?

Summary

How does Biofrontera compare to Tenax Therapeutics?

Summary

How does Biofrontera compare to Cingulate?

Summary

How does Biofrontera compare to Verrica Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI vs. The Competition

Biofrontera Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biofrontera (BFRI) Competitors

BFRI vs. ZYBT, ICCC, TENX, CING, and VRCA

How does Biofrontera compare to Zhengye Biotechnology?

Which has more volatility and risk, BFRI or ZYBT?

Does the media prefer BFRI or ZYBT?

Do analysts recommend BFRI or ZYBT?

Do institutionals and insiders believe in BFRI or ZYBT?

Is BFRI or ZYBT more profitable?

Which has stronger earnings & valuation, BFRI or ZYBT?

Summary

How does Biofrontera compare to ImmuCell?

Which has more volatility and risk, BFRI or ICCC?

Is BFRI or ICCC more profitable?

Which has better valuation and earnings, BFRI or ICCC?

Do institutionals & insiders hold more shares of BFRI or ICCC?

Does the media refer more to BFRI or ICCC?

Do analysts prefer BFRI or ICCC?

Summary

How does Biofrontera compare to Tenax Therapeutics?

Is BFRI or TENX more profitable?

Do institutionals and insiders hold more shares of BFRI or TENX?

Which has more risk and volatility, BFRI or TENX?

Which has higher earnings and valuation, BFRI or TENX?

Do analysts rate BFRI or TENX?

Does the media favor BFRI or TENX?

Summary

How does Biofrontera compare to Cingulate?

Is CING or BFRI more profitable?

Do institutionals and insiders hold more shares of CING or BFRI?

Which has better valuation and earnings, CING or BFRI?

Do analysts prefer CING or BFRI?

Does the media refer more to CING or BFRI?

Which has more risk and volatility, CING or BFRI?

Summary

How does Biofrontera compare to Verrica Pharmaceuticals?

Which has stronger earnings and valuation, BFRI or VRCA?

Which has more volatility and risk, BFRI or VRCA?

Is BFRI or VRCA more profitable?

Does the media favor BFRI or VRCA?

Do insiders and institutionals hold more shares of BFRI or VRCA?

Do analysts rate BFRI or VRCA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI vs. The Competition

Biofrontera Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools